Spots Global Cancer Trial Database for Sacituzumab Govitecan in Recurrent Glioblastoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Sacituzumab Govitecan in Recurrent Glioblastoma
Official Title: A Phase II, Multicenter, Prospective Study of Sacituzumab Govitecan in Recurrent Glioblastoma
Study ID: NCT04559230
Conditions
Interventions
Study Description
Brief Summary: This is an open-label single arm study. All patients will receive the investigational agent.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
Texas Oncology, Dallas, Texas, United States
University of Texas Health Science Center San Antonio at the Cancer Therapy and Research Center, San Antonio, Texas, United States
Contact Details
Name: William Kelly, MD
Affiliation: Mays Cancer Center, UT Health San Antonio
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
